Journal of Pharmacogenomics & Pharmacoproteomics

Journal of Pharmacogenomics & Pharmacoproteomics
Open Access

ISSN: 2153-0645


Tatjana Abaffy

Tatjana Abaffy

Miller School of Medicine, Miami, Florida

  • Editorial
    Cancer Research Strategies and Cancer Care
    Author(s): Tatjana AbaffyTatjana Abaffy

    Imatinib mesylate (Gleevec) is a tyrosine kinase inhibitor currently used for treatment of BCR-ABL (Breakpoint Cluster Region–vabl ABelson murine Leukemia viral oncogene) Tyrosine Kinase (TK) positive leukemia, as well as GastroIntestinal Stromal Tumors (GIST). Imatinib represents one of the rare successful stories in drug development [1]. Imatinib binds to the catalytic site of the kinase and traps it in an inactive conformation. This success was made possible through decades of intensive and collaborative research which led to discovery of the involvement of this protein kinase in tumor pathology. However, this success though impressive, was not immortal. A resistance to the drug developed. Drug resistance is often associated with chronic treatment with anticancer drugs and is likely due to the general genomic instability well documented in cancer. It has been sho.. Read More»
    DOI: 10.4172/2153-0645.1000e103

    Abstract PDF

Relevant Topics